318 completed, 54 terminated, 42 unknown, 27 recruiting. 126 Phase 4, 123 Phase 2, 96 Phase 3, 61 Phase 1, 47 Not applicable.
Follow Pioglitazone: new trials by email Literature Review of Pioglitazone trials Research Report on Pioglitazone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis Rezdiffra, Resmetirom, ACTOS/pioglitazone - MASH - Metabolic Dysfunction-Associated Steatohepatitis | Phase 4 | Recruiting | Madrigal Pharmaceuticals, Inc. | 150 | 2026-10-07 | 2026-10-16 |
| SGLT2i, Pioglitazone, and Ketone Production in T1D Dapagliflozin 10mg Tab, Pioglitazone 15 MG and 30mg, Placebo - Type1diabetes | Phase 3 | Recruiting | The University of Texas Health Science Center at San Antonio | 24 | 2026-07-01 | 2026-07-20 |
| Enhancing PCOS Management for Better Outcomes of Intracytoplasmic Sperm Injection Metformin monotherapy, Myoinositol and metformin, pioglitazone and metformin - Polycystic Ovarian Syndrome (PCOS) | Not applicable | Active not recruiting | Beni-Suef University | 150 | 2026-05-17 | 2026-05-22 |
| SGLT2i, Pioglitazone, and Ketone Production in T2D Empagliflozin 25 MG, Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d) - Type 2 Diabetes | Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 64 | 2026-05-11 | 2026-07-17 |
| A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants AZD5004, Mitiglinide, Pioglitazone - Healthy Participants | Phase 1 | Completed | AstraZeneca | 32 | 2026-03-13 | 2026-07-13 |
| Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate Clomiphene Citrate., Pioglitazone (PIO) + Clomiphene citrate - Infertility Treatment, Pregnancy Rates | Phase 4 | Recruiting | PAEC General Hospital, Islamabad | 62 | 2026-03-01 | 2026-03-10 |
| Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease Pioglitazone (PIO), Empagliflozin, Statin (Atorvastatin) - Non-alcoholic Fatty Liver Disease NAFLD, Non-alcoholic Steatohepatitis NASH | Phase 4 | Not yet recruiting | Badr University | 400 | 2025-11-01 | 2025-09-18 |
| An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy L-Ornithine L-Aspartate, CDK4/6 inhibitor, Fulvestrant - Breast Cancer | Phase 2 | Recruiting | Fudan University | 60 | 2025-09-25 | 2026-07-13 |
| Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration? Dapagliflozin (DAPA), Pioglitazone 45 mg, Placebo - Type 1 Diabetes | Phase 4 | Not yet recruiting | Dasman Diabetes Institute | 60 | 2025-09-15 | 2025-08-29 |
| A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed) Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg - Diabete Mellitus | Phase 1 | Recruiting | Boryung Pharmaceutical Co., Ltd | 40 | 2025-07-05 | 2025-07-24 |
| A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting) Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg - Diabetes Mellitus | Phase 1 | Recruiting | Boryung Pharmaceutical Co., Ltd | 52 | 2025-07-03 | 2025-07-24 |
| A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes Metformin, Dapagliflozin/Pioglitazone, Dapagliflozin/Sitagliptin - Type 2 Diabetes | Phase 4 | Recruiting | Boryung Pharmaceutical Co., Ltd | 204 | 2025-06-11 | 2025-09-15 |
| Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus Pioglitazone (PIO), Empagliflozin (EMPA) - Pancreatitis, Chronic, Pancreatitis, Acute | Phase 2 | Recruiting | Mayo Clinic | 50 | 2025-05-29 | 2026-07-29 |
| Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. Metformin, Dulaglutide, Semaglutide 1.0 mg - Diabetes Mellitus Type 2 | Phase 4 | Completed | Fundación para la Investigación del Hospital Clínico de Valencia | 92 | 2025-05-26 | 2026-09-04 |
| Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide Insulin resistance testing, OGTT, Fat biopsy - Diabetes Mellitus, Type 2, Diabetes | Phase 4 | Recruiting | Stanford University | 104 | 2025-01-13 | 2026-04-20 |
| Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes Pioglitazone 15 MG [Actos], Empagliflozin 10 MG [Jardiance], Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos] - Type 2 Diabetes, Fatty Liver | Phase 4 | Recruiting | Seoul National University Bundang Hospital | 120 | 2025-01-01 | 2025-05-25 |
| Bioenergetic Effect of Pioglitazone in CLD-PH Pioglitazone 30mg, Placebo, Labs - Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases | Phase 2 | Recruiting | Emory University | 20 | 2024-12-17 | 2026-07-22 |
| Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes Tirzepatide, Pioglitazone, Sitagliptin - Type 2 Diabetes (Adult Onset) | Phase 3 | Recruiting | The University of Texas Health Science Center at San Antonio | 256 | 2024-11-07 | 2026-03-10 |
| The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats standard normal diet, low dose Streptozotocin, Sitagliptin (Novartis, USA) - Diabetic, Myocardial Infarction | Phase 4 | Completed | Al-Azhar University | 50 | 2024-10-30 | 2025-08-14 |
| Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus PIEMONTE, PIEMONTE PLACEBO, EMPAGLIFLOZIN - Type II Diabetes | Phase 3 | Recruiting | EMS | 480 | 2024-10-08 | 2025-12-08 |
Showing 20 of 465. Sign in to see all of them.
Diabetes Mellitus, Type 2 (208) · Diabetes Mellitus (90) · Insulin Resistance (54) · Dyslipidemias (28) · Glucose Metabolism Disorders (28) · Non-alcoholic Fatty Liver Disease (23) · Obesity (21) · Diabetes Mellitus, Lipoatrophic (18) · Metabolic Syndrome (16) · Glucose Intolerance (13) · Fatty Liver (12) · Inflammation (12) · Atherosclerosis (10) · Hyperglycemia (10) · Polycystic Ovary Syndrome (10)
Takeda (51) · AstraZeneca (15) · The University of Texas Health Science Center at San Antonio (14) · Merck Sharp & Dohme LLC (10) · Boehringer Ingelheim (8) · Emory University (7) · GlaxoSmithKline (7) · Hoffmann-La Roche (7) · University of Texas Southwestern Medical Center (7) · Daiichi Sankyo (6) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (6) · Stanford University (6) · Boryung Pharmaceutical Co., Ltd (5) · Mayo Clinic (5) · Pennington Biomedical Research Center (5)
United States (227) · Germany (40) · South Korea (33) · Mexico (31) · United Kingdom (26) · Canada (24) · India (24) · Argentina (19) · Italy (18) · Puerto Rico (17) · Russia (16) · Australia (15) · China (15) · France (15) · Peru (15)
PMID 33210751, PMID 19744248, PMID 23795975, PMID 32803882, PMID 20959530, PMID 21680990, PMID 23522121, PMID 23748506, PMID 23748507, PMID 27033025, PMID 27402391, PMID 28096223, PMID 32306296, PMID 33368935, PMID 39584361, PMID 1386652, PMID 14998615, PMID 15220241, PMID 15277411, PMID 15339912, PMID 15611492, PMID 15632102, PMID 15677776, PMID 15983299, PMID 16046295, PMID 16118250, PMID 16214598, PMID 16249569, PMID 16368057, PMID 16508777, PMID 16799131, PMID 16803857, PMID 16855265, PMID 16894240, PMID 16968813, PMID 17003347, PMID 17090638, PMID 17101640, PMID 17130488, PMID 17135584, PMID 17166340, PMID 17192117, PMID 17199725, PMID 17223044, PMID 17240282, PMID 17251278, PMID 17286868, PMID 17290029, PMID 17300592, PMID 17327456
2008 (4), 2009 (3), R01DK024092 (3), 2005 (2), 2015 (2), 2004 (1), 2014 (1), 2025 (1), K23DK079789 (1), K23DK124647 (1), K23HL166775 (1), KL2RR024151 (1), N01CN00042 (1), N01CN35000 (1), N01CN35153 (1)